<DOC>
	<DOCNO>NCT00816634</DOCNO>
	<brief_summary>Until today , 5-FU/cisplatin combination reference regimen 30-45 % response rate , commonly use treat patient metastatic , recurrent locally advanced , unresectable squamous cell carcinoma esophagus . Because classical dose schedule two-drug combination cisplatin 100 mg/m2 day 1 5-FU 1000 mg/m2/day continuous infusion 96-120 hr , prolonged administration time mucosal toxicity inconvenient patient aim palliation . Capecitabine , oral prodrug 5-FU mimic continuously-infused 5-FU , investigated phase I , II III trial treatment gastric , gastroesophageal , esophageal cancer , primarily first-line metastatic setting . In experience , capecitabine plus cisplatin combination ( XP ) first-line treatment 45 patient advanced recurrent esophageal squamous cell carcinoma demonstrate promising anti-tumor activity 57 % response rate show tolerable toxicity convenience . Paclitaxel also investigate monotherapy combination cisplatin patient advanced esophageal cancer . A Dutch phase II study demonstrate paclitaxel combination carboplatin show encourage confirm response rate 59 % 51 patient resectable esophageal cancer neoadjuvant setting . Another Dutch phase II study show 43 % response rate include 4 % CR 8 month response duration paclitaxel plus cisplatin administration give patient metastatic esophageal cancer . Although recently first-line palliative chemotherapy regimen esophageal cancer investigate , many trial fail show superiority 5-FU/cisplatin combination . Since consider XP XT effective convenient chemotherapy regimen 5-FU/cisplatin , randomized phase II study plan compare XP XT term efficacy tolerability .</brief_summary>
	<brief_title>Efficacy Comparison Study Combination Regimens Treat Advanced Esophageal Squamous Cell Carcinoma</brief_title>
	<detailed_description>1 . Introduction Study Rationale 1.1 Esophageal squamous cell carcinoma Esophageal cancer seventh common cancer Korea , almost 400,000 new patient diagnose annually worldwide . There large variation predominant histological type throughout world majority worldwide esophageal cancer squamous cell carcinoma arise upper middle third esophagus . Esophageal cancer highly virulent disease five-year survival rate 10-15 % . Metastatic esophageal carcinoma incurable disease median survival duration 6 8 month . 1.2 5-FU plus Cisplatin ( FP ) combination chemotherapy Cytotoxic chemotherapy use control tumor growth , improve quality life prolong survival although survival advantage chemotherapy best supportive care alone patient metastatic cancer esophagus proven randomize trial . Although standard chemotherapy regimen metastatic esophageal cancer , various kind chemotherapy regimen use alleviate symptom cause cancer prolong survival improve quality life . Various phase-II trial perform evaluate effect chemotherapy . The activity conventional single agent chemotherapy study cisplatin , 5-FU mitomycin , induced response rate 15-30 % . In study , chemotherapy regimen consist combination cisplatin another agent 5-FU etoposide squamous cell carcinoma adenocarcinoma . The commonly use chemotherapy regimen patient advanced esophageal cancer combination 5-FU cisplatin , response rate range 15 % 45 % , however , effect survival remain undetermined . 1.2 Capecitabine esophageal cancer Capecitabine novel , orally administer fluoropyrimidine carbamate absorb readily gastrointestinal tract metabolize liver , convert initially 5 -deoxy-5-fluorocytidine ( 5 -DFCR ) subsequently , 5 -deoxy-5-fluorouridine ( 5 -DFUR ) . Designed mimic continuous intravenous ( CIV ) 5-FU , oral capecitabine predominantly concentrate tumor tissue . Capecitabine currently approve single agent adjuvant treatment stage III colon cancer , first-line treatment metastatic colorectal cancer , metastatic breast cancer single agent patient combination docetaxel . Whether oral fluoropyrimidines may appropriately substitute , therefore make therapy le burdensome patient reduce need infusion catheter , fully investigate In patient advanced esophagogastric cancer , capecitabine combination generally show good antitumor activity highlight potential capecitabine replacement infusional 5-FU . Capecitabine investigated combination cisplatin docetaxel phase II trials patient advanced esophageal cancer observe response rate 47.1 % 46 % , respectively . In recent phase III trial compare efficacy capecitabine/cisplatin ( XP ) versus FP advance gastric cancer , XP inferior FP , term progression-free survival ( PFS ) , overall survival ( OS ) , response rate ( RR ) . In experience , combination capecitabine cisplatin esophageal cancer show encouraging response rate ( 59 % ) tolerable toxicity convenience . 1.3 Paclitaxel esophageal cancer Paclitaxel combination cisplatin show favorable result advance esophageal carcinoma . A recent phase II study bi-weekly administration paclitaxel cisplatin 51 patient result complete response 4 % , partial response 39 % , stable disease 43 % progressive disease 14 % patient , one-year survival 43 % . Several phase II trial assess combination taxanes ( paclitaxel docetaxel ) cisplatin agent , response rate 40-56 % . 1.4 Capecitabine plus Paclitaxel combination esophageal cancer Capecitabine combination docetaxel great efficacy single-agent docetaxel ; combination increase survival significantly compare single-agent docetaxel ( 14.5 v 11.5 month ) patient metastatic breast cancer experience disease progression anthracycline therapy . The common treatment-related adverse event ( TRAEs ) , capecitabine 1,250 mg/m2 bid docetaxel 75 mg/m2 alopecia , hand-foot skin reaction ( HFS ) , nausea , fatigue . Neutropenia ( 15 % ) HFS ( 11 % ) grade 3 4 TRAEs occur 10 % patient . In trial tolerable deliver dose capecitabine patient 950 mg/m2 bid 14 day . Lorenzen et al . treat 24 patient capecitabine dose 1000 mg/m2 twice daily Days 1 14 docetaxel 75 mg/m2 Day 1 3-week cycle . The RR 46 % median survival 15.8 month . However , toxicity profile high two 2 treatment-related death , high incidence Grade 3 4 neutropenia ( 42 % ) , high incidence Grade 3 HFS ( 29 % ) . There theoretical advantage use paclitaxel weekly schedule conjunction capecitabine base duration upregulation thymidine phosphorylase ( dThPase ) paclitaxel model system . The metabolism capecitabine active agent , FU , provide insight rationale combine capecitabine taxanes phase II study . The rationale combining paclitaxel capecitabine base upregulation dTHPase , demonstrate model athymic mouse bear capecitabine-resistant human colon cancer xenograft . Treatment paclitaxel lead 7.9-fold increase intratumoral dThPase . An increase dThPase activity occur 4 day treatment paclitaxel persist 10 day . These data lead current concept clinical trial , use paclitaxel day 1 8 14-day exposure capecitabine patient MBC . Moreover , agent nonoverlapping toxicity therefore combine reasonable tolerability . It anticipate allow week weekly paclitaxel therapy , frequency sensory neuropathy could reduce . Given high degree efficacy docetaxel/capecitabine combination , significant toxicity observe 1,250 mg/m2 bid capecitabine schedule , well promise efficacy safety observe weekly paclitaxel/capecitabine phase I study Uhlmann et al [ 27 ] , choose weekly paclitaxel combination regimen capecitabine . Practically , study regimen capecitabine plus paclitaxel ( XT ) combination chemotherapy . 1.5 XP v XT esophageal cancer Based rationale experience , go conduct randomize phase II trial metastatic esophageal cancer evaluate efficacy feasibility compare XP XT . 2 . Study Objectives 2.1 Primary Objective : To evaluate response rate treatment group ( XP v XT ) metastatic esophageal cancer . 2.2 Secondary Objectives : 1. toxicity 2. progression-free survival 3. quality life 4. overall survival 5. predictive marker study influence response survival 3 . Study Design 3.1 Randomization 1 . Timing randomization : Randomization perform inclusion patient 2 . Stratification factor : performance status ( ECOG 0 , 1 v 2 ) &amp; weight loss 10 % 3.2 Overview Study Design This study prospective , randomize , phase II study compare response rate patient XP chemotherapy versus XT chemotherapy patient metastatic squamous cell carcinoma . Chemotherapy regimen ( XP ) : D1- D14 Capecitabine 1000 mg/m2 bid p.o . D1 Cisplatin 75 mg/m2 + NS 150mL MIV 1hr Pre &amp; Post medication D0 N/S 1500 mL IV overnight hydration D1 DNK2 1000 mL IV 2 hour , pre &amp; post hydration ( Mg &lt; WNL , mix MgSO4 1 amp ) 5-HT3 antagonist 1 amp + dexamethasone 20 mg + D5W 100 mL MIV 20 % Mannitol 70 mL IV full dripping , 30 min cisplatin D2-D5 5-HT3 antagonist 1T QD D2-D3 Dexamethasone 8 mg PO bid D4-D5 Dexamethasone 4 mg PO bid every 3 week Chemotherapy regimen ( XT ) : D1- D14 Capecitabine 1000 mg/m2 bid p.o . D1 , D8 Paclitaxel 80 mg/m2 + D5W 500mL MIV 3hrs Pre &amp; Post medication D1 , D8 Solucortef 100 mg IV push Paclitaxel Avil 1A + D5W 50mL MIV 30mins Taxol Ranitidine 50mg IV + D5W 50mL MIV 30mins Paclitaxel HT3 antagonist 1A + D5W 50 mL MIV 30mins Paclitaxel Followed 1 week every 3 week 3.3 Study Duration Dates The duration study expect 36 month , subject recruitment propose start October 2008 . The actual overall study duration subject recruitment period may vary . 3.4 Number Patients/Assignment Treatment Groups 94 patient recruited total . Patients randomize treatment arm permutated method . Chemotherapy start within 14 day randomization .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1 . Histologically confirm metastatic , recurrent esophageal squamous cell carcinoma 2 . Age &gt; 18 year 3 . ECOG performance status 0 2 4 . At least one measurable lesion ( ) RECIST criterion 5 . Life expectancy ≥ 3 month 6 . Patients may receive prior adjuvant chemotherapy 5FU cisplatin long 12 month since completion regimen . 7 . No previous palliative chemotherapy 8 . Prior radiotherapy must complete 4 week study entry . 9 . Adequate bone marrow function ( ≥ ANC 1,500/ul , ≥ platelet 100,000/ul , ≥ Hemoglobin 9.0 g/dl ) 10 . Adequate renal function ( ≤ serum creatinine 1.5 mg/dl CCr ≥ 50 ml/min ) 11 . Adequate liver function ( ≤ serum bilirubin 1.5 mg/dl , ≤ AST/ALT x 3 upper normal limit ) 12 . Written inform consent 1 . Other tumor type adenocarcinoma , small cell carcinoma 2 . Evidence CNS metastasis 3 . Contraindication drug contain chemotherapy regimen 4 . Previous adjuvant treatment 5FU , cisplatin , capecitabine paclitaxel finish less 1 year 5 . Evidence serious gastrointestinal bleeding 6 . History another malignancy within last five year except cure basal cell carcinoma skin cure carcinoma insitu uterine cervix 7 . Clinically significant cardiac disease ( e.g . severe noncompensated hypertension , noncompensated heart failure , dilate cardiomyopathy , coronary heart disease ST segment depression ECG ) myocardial infarction within last 6 month . 8 . Serious pulmonary conditions/illness ( e.g . chronic lung disease hypoxemia ) 9 . Serious metabolic disease severe noncompensated diabetes mellitus 10 . History significant neurologic psychiatric disorder 11 . Serious uncontrolled intercurrent infection , serious uncontrolled concomitant disease 12 . Positive serology HIV 13 . Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>First line chemotherapy</keyword>
	<keyword>Advanced recurrent esophageal squamous cell carcinoma</keyword>
</DOC>